Cargando…

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

INTRODUCTION: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Lars, Hunt, Barnaby, Johansen, Pierre, Iyer, Neeraj N., Dang-Tan, Tam, Pollock, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984908/
https://www.ncbi.nlm.nih.gov/pubmed/29557057
http://dx.doi.org/10.1007/s13300-018-0402-8
_version_ 1783328676765499392
author Wilkinson, Lars
Hunt, Barnaby
Johansen, Pierre
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
author_facet Wilkinson, Lars
Hunt, Barnaby
Johansen, Pierre
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
author_sort Wilkinson, Lars
collection PubMed
description INTRODUCTION: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide in the USA. METHODS: Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective. RESULTS: More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints. The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg. The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg. For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg. CONCLUSIONS: The cost of bringing one patient to the triple composite endpoint of an HbA1c < 7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg relative to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Once-weekly semaglutide therefore provides better value for money than dulaglutide for the treatment of people with T2D in the USA. FUNDING: Novo Nordisk A/S.
format Online
Article
Text
id pubmed-5984908
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-59849082018-06-13 Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States Wilkinson, Lars Hunt, Barnaby Johansen, Pierre Iyer, Neeraj N. Dang-Tan, Tam Pollock, Richard F. Diabetes Ther Original Research INTRODUCTION: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide in the USA. METHODS: Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective. RESULTS: More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints. The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg. The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg. For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg. CONCLUSIONS: The cost of bringing one patient to the triple composite endpoint of an HbA1c < 7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg relative to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Once-weekly semaglutide therefore provides better value for money than dulaglutide for the treatment of people with T2D in the USA. FUNDING: Novo Nordisk A/S. Springer Healthcare 2018-03-19 2018-06 /pmc/articles/PMC5984908/ /pubmed/29557057 http://dx.doi.org/10.1007/s13300-018-0402-8 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Wilkinson, Lars
Hunt, Barnaby
Johansen, Pierre
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title_full Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title_fullStr Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title_full_unstemmed Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title_short Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
title_sort cost of achieving hba1c treatment targets and weight loss responses with once-weekly semaglutide versus dulaglutide in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984908/
https://www.ncbi.nlm.nih.gov/pubmed/29557057
http://dx.doi.org/10.1007/s13300-018-0402-8
work_keys_str_mv AT wilkinsonlars costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates
AT huntbarnaby costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates
AT johansenpierre costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates
AT iyerneerajn costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates
AT dangtantam costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates
AT pollockrichardf costofachievinghba1ctreatmenttargetsandweightlossresponseswithonceweeklysemaglutideversusdulaglutideintheunitedstates